company background image
TLRY

Tilray Brands NasdaqGS:TLRY Stock Report

Last Price

US$1.86

Market Cap

US$1.1b

7D

-22.8%

1Y

-59.1%

Updated

26 May, 2023

Data

Company Financials +

TLRY Stock Overview

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.

TLRY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Tilray Brands, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tilray Brands
Historical stock prices
Current Share PriceUS$1.86
52 Week HighUS$5.12
52 Week LowUS$1.82
Beta2.42
1 Month Change-14.68%
3 Month Change-34.04%
1 Year Change-59.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.45%

Recent News & Updates

Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues

Apr 17
Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues

Recent updates

Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues

Apr 17
Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues

An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 28% Undervalued

Feb 03
An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 28% Undervalued

Tilray Brands, Inc.'s (NASDAQ:TLRY) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 09
Tilray Brands, Inc.'s (NASDAQ:TLRY) Intrinsic Value Is Potentially 97% Above Its Share Price

Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review

Oct 06

Japan should permit medical cannabis, health ministry panel says

Sep 29

Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment

Sep 21

Tilray's Canadian cannabis brand RIFF launches Drumsticks

Sep 15

Tilray: Hype Train Crashed

Sep 08

Tilray Brands: No One Is Happy

Sep 01

Tilray gets non-profit NHSF nod for use of CBD100 in trials in Australia, New Zealand

Aug 23

Tilray gets approval in Poland to commercialize medical cannabis products

Aug 17

Tilray Brands inks CBD beverage distribution deal with Southern Glazer’s

Aug 03

Will Tilray Q4 result bring earnings surprise?

Jul 27

With Tilray's $155M investment in HEXO, Roth Capital sees cannabis headwinds and softness

Jul 15

Tilray's Good Supply brand expands product offering in Québec

Jul 06

Tilray Medical expands portfolio of medical cannabis products in the United Kingdom

Jun 29

Tilray Stock: Don't Even Think About It

Jun 16

Tilray Brands: Almost Good Enough

May 17

Tilray Short Interest Hits New High

May 11

Robust Earnings May Not Tell The Whole Story For Tilray Brands (NASDAQ:TLRY)

Apr 14
Robust Earnings May Not Tell The Whole Story For Tilray Brands (NASDAQ:TLRY)

Tilray Reports Positive Earnings: Look Beyond The Headline Numbers

Apr 07

Decriminalization Buzz is Moving Tilray (NASDAQ:TLRY), but The Company may have some Significant Issues

Mar 25
Decriminalization Buzz is Moving Tilray (NASDAQ:TLRY), but The Company may have some Significant Issues

Tilray: Keeping Competition Alive

Mar 25

Tilray Brands: The Big Money Is Still In The US

Feb 11

Quick Take On Tilray's Recent Disappointing Earnings

Jan 24

Tilray's (NASDAQ:TLRY) Earnings Need a Scratch Below the Surface

Jan 12
Tilray's (NASDAQ:TLRY) Earnings Need a Scratch Below the Surface

Tilray: Sell Dead Cat Bounce

Jan 10

Tilray: $4 Billion Market Opportunity In German Adult Recreational Cannabis

Dec 03

Calculating The Fair Value Of Tilray, Inc. (NASDAQ:TLRY)

Nov 12
Calculating The Fair Value Of Tilray, Inc. (NASDAQ:TLRY)

Is Tilray Stock A Buy, Sell, Or Hold After Recent Earnings?

Oct 27

Is Tilray Stock Overvalued Or Undervalued? Still Overvalued Now, But Looking Cheap Enough

Oct 18

Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders

Oct 08
Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders

Tilray: Out Of Touch

Oct 07

Shareholder Returns

TLRYUS PharmaceuticalsUS Market
7D-22.8%-2.9%0.3%
1Y-59.1%-4.9%-0.7%

Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.

Return vs Market: TLRY underperformed the US Market which returned -0.7% over the past year.

Price Volatility

Is TLRY's price volatile compared to industry and market?
TLRY volatility
TLRY Average Weekly Movement10.6%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.5%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TLRY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20181,700Irwin Simonhttps://www.tilray.com

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.

Tilray Brands, Inc. Fundamentals Summary

How do Tilray Brands's earnings and revenue compare to its market cap?
TLRY fundamental statistics
Market CapUS$1.15b
Earnings (TTM)-US$1.79b
Revenue (TTM)US$596.26m

1.9x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLRY income statement (TTM)
RevenueUS$596.26m
Cost of RevenueUS$519.97m
Gross ProfitUS$76.29m
Other ExpensesUS$1.87b
Earnings-US$1.79b

Last Reported Earnings

Feb 28, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.90
Gross Margin12.79%
Net Profit Margin-300.55%
Debt/Equity Ratio17.4%

How did TLRY perform over the long term?

See historical performance and comparison